Genomic Cancer Testing Market Growth Accelerated by Early Detection and Personalized Treatment
Genomic cancer testing enables comprehensive analysis of
cancer susceptibility and progression at the molecular level. These tests
examine genetic variations and mutations to determine risk of cancer
development and select optimal targeted therapies. They aid in early detection
of cancer and development of customized treatment plans based on patient's
genetic profile.
The global Genomic Cancer Testing Market is estimated to be
valued at US$ 18.61 million in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period
2024 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The increasing adoption of genomic cancer testing is mainly driven by the
trend of precision medicine. Genomic profiling enables personalized cancer care
by identifying targeted drugs and immunotherapy options best suited for a
patient's unique genetic mutations and tumor characteristics. This personalized
approach has significantly improved treatment outcomes. Technical advancements
have made these tests more affordable and accessible. Ongoing R&D to
discover new cancer biomarkers is also expanding clinical applications of
genomic cancer testing.
Segment Analysis
Genomic Cancer Testing Market
The global
genomic cancer testing market size is dominated by the breast cancer
sub-segment, owing to the increasing prevalence and incidence rates. Breast
cancer accounts for nearly one-fourth of all new cancer cases in women worldwide.
Early and accurate diagnosis plays a major role in breast cancer management.
Genomic testing helps oncologists design personalized treatment plans and
monitor cancer recurrence.
Key Takeaways
The global Genomic Cancer Testing market is expected to witness high growth
over the forecast period.
Regional analysis North America currently dominates the
Genomic Cancer Testing market owing to supportive government initiatives
focused on precision medicine research and presence of major market players.
For instance, in 2015 the National Cancer Institute and National Human Genome
Research Institute launched The Cancer Genome Atlas to enable comprehensive
mapping of major cancer types.
Key players operating in the Genomic Cancer Testing market are Bitmain
Technologies, MicroBT, Canaan Creative, NVIDIA, AMD, Genesis Mining, Bitfury
Group, Hut 8 Mining Corp., Riot Blockchain, Marathon Digital Holdings, Hive
Blockchain Technologies. Bitmain Technologies, MicroBT and Canaan Creative
currently dominate the market owing to their expertise and experience in the
field of genomic cancer testing equipment manufacturing.
Get
more insights on this topic: https://www.ukwebwire.com/genomic-cancer-testing-market-share-and-opportunity-analysis/
Explore
more trending article on this topic: https://masstamilan.tv/parp-inhibitors-a-promising-class-of-drugs-in-cancer-treatment/
Comments
Post a Comment